AFM
QNCX icon

Anson Funds Management’s Quince Therapeutics QNCX Stock Holding History

Anson Funds Management’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-325
Closed -$821K – 415
2021
Q4 		$821K Buy
+325
New +$1.98M 0.08% 196

Other funds holding QNCX

ECG
EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Voloridge Investment Management
Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Anson Funds Management's QNCX Position: Q1 2022 in Review

Anson Funds Management sold out of Quince Therapeutics (QNCX) in Q1 2022, closing a stake of 325 shares — an estimated $821K sold.

Anson Funds Management first reported a position in QNCX in Q4 2021 and held it in 1 quarter. The position peaked at $821K in Q4 2021. 85 funds tracked by Wall St. Rank hold QNCX as of Q1 2022.

  • Anson Funds Management reported no remaining Quince Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Anson Funds Management sold 325 Quince Therapeutics shares in Q1 2022, an estimated $821K.
  • Anson Funds Management first reported a position in Quince Therapeutics in Q4 2021 and held it in 1 quarter.
  • Anson Funds Management's Quince Therapeutics position peaked at $821K in Q4 2021.
  • 85 funds tracked by Wall St. Rank held Quince Therapeutics as of Q1 2022.

Based on Anson Funds Management's 13F filing for Q1 2022, filed 12 May 2022.